Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-29T21:47:07.757Z Has data issue: false hasContentIssue false
  • English
  • Français

Histamine intolerance and anxiety disorders: pilot cross-sectional study of histamine intolerance prevalence in cohort of patients with anxiety disorders

Published online by Cambridge University Press:  01 September 2022

E. Nosková ,
K. Vochosková ,
V. Knop ,
P. Stopková  and
M. Kopeček
E. Nosková*
Affiliation:
Charles University in Prague, Third Faculty Of Medicine, Prague, Czech Republic National Institute of Mental Health, Medical Care, Klecany, Czech Republic
K. Vochosková
Affiliation:
Charles University in Prague, Third Faculty Of Medicine, Prague, Czech Republic National Institute of Mental Health, Medical Care, Klecany, Czech Republic
V. Knop
Affiliation:
National Institute of Mental Health, Medical Care, Klecany, Czech Republic
P. Stopková
Affiliation:
Charles University in Prague, Third Faculty Of Medicine, Prague, Czech Republic National Institute of Mental Health, Medical Care, Klecany, Czech Republic
M. Kopeček
Affiliation:
Charles University in Prague, Third Faculty Of Medicine, Prague, Czech Republic National Institute of Mental Health, Medical Care, Klecany, Czech Republic
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Histamine intolerance (HI) is a disorder associated with an impairment of ability to metabolize ingested histamine. The incidence of HI in general population is 1-3%. Clinical manifestation of HI contains nonspecific predominantly gastrointestinal, but also extraintestinal symptoms. HI could be primary with genetic predisposition, or secondary with lower activity of diaminooxidase (DAO) without positive genetic screening.

Objectives

This study aims to evaluate the prevalence of HI by patients with anxiety disorders. HI can imitate anxiety symptoms, therefore we predict higher prevalence HI in patients with anxiety disorders than in general population.

Methods

It is observational cross-sectional study on cohort of anxious patients for detecting the prevalence of HI. Patients were screened by scale for histamine intolerance questionnaire. Patients with positive questionnaire were examined for serum DAO and genetically examined.

Results

113 patients fulfilled the HI questionnaire. From this cohort 35.4% (40 subjects) were positive at screening. Biomarkers of HI were screened only in case of positivity in this questionnaire. Table No. 1: Results of our study from cohort with positive screening, 35.4 % (40 subjects).

Genetic predisposition
positivity in risk allelenegativity in risk allelealtogether
Serum level of DAOpositive screening (DAO<10 U/ml)5 (4.4%) primary-genetically determined HI5 (4.4%) secondary HI10
negative screening (DAO≥10 U/ml)14 (12.4%)16 (14.2%)30
altogether1921

Conclusions

This pilot study shows that the prevalence of HI could be higher in group of patients with anxiety disorders than in general population. For further confirmation other studies with control group and larger cohort should be done.

Disclosure

No significant relationships.

Keywords

anxiety symptomsdiaminooxidasegenetic examinationhistamine intolerance
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S387 - S388
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.